Background: Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of Temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas.
Patients and methods: Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received Temozolomide as salvage therapy and results were received retrospectively.
Results: Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to Temozolomide.
Conclusion: In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy Temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma.
chemotherapy - recurrent glioma - temozolomide